TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04445948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetroNIDAZOLE 500 milligrams Oral Tablet
Description: Antiprotozoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetroNIDAZOLE 500 milligrams Oral Tablet
Description: Antiprotozoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine sachets 200 milligrams
Description: a protein found naturally in milk from humans and cows

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine sachets 200 milligrams
Description: a protein found naturally in milk from humans and cows
Study: NCT00006604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Study: NCT00474604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: A scan will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: A scan will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: A scan will be performed.
Study: NCT04711213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Dose 1
Description: Dexamethasone ophthalmic suspension dose 1
Study: NCT00006604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered as 100 mg capsules or oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered as 100 mg capsules or oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered as 100 mg capsules or oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered as 100 mg capsules or oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered as 100 mg capsules or oral solution.
Study: NCT00474604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic resonance spectroscopic imaging
Description: A scan will be performed.
Study: NCT04301245

Intervention type: OTHER
Intervention: Educational program
Description: The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment.

Intervention type: OTHER
Intervention: Educational program
Description: The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment.
Study: NCT02135406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 T cells
Study: NCT03358160

Intervention type: BEHAVIORAL
Intervention: Action discrimination tasks.
Description: The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.

Intervention type: BEHAVIORAL
Intervention: Action discrimination tasks.
Description: The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.

Intervention type: BEHAVIORAL
Intervention: Action discrimination tasks.
Description: The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
Study: NCT02059330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75mg
Description: In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 100mg
Description: In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study: NCT04154826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-7
Description: weekly intra-muscular (IM) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-7
Description: weekly intra-muscular (IM) administration
Study: NCT04953416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1565nm non ablative fractional laser
Description: The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
Study: NCT01312181

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthCall and Motivational Interviewing
Description: Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV/AIDS health education
Description: The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
Study: NCT02214719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASI-IDM use
Description: EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
Study: NCT01322971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500mg orally twice daily for seven days
Study: NCT01398033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-coated balloon
Description: Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
Study: NCT03666390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
Study: NCT02476448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Used to distend the bladder for cystoscopic evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Description: Administered orally preoperatively and assessed during cystoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 10%
Description: Used to distend the bladder for cystoscopic evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: Administered intravenously and assessed during cystoscopy
Study: NCT02645864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m\^2 i.v. q2w
Study: NCT01468480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro Root MTA
Description: application of MTA in second group and 24 hour interval before restoration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro Root MTA- single visit
Description: application of MTA in third group and 15 minute interval before restoration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiCal
Description: application of Multical in forth group as a pulp dressing agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dycal
Description: application of Dycal in first group as a pulp dressing agent
Study: NCT01758094

Intervention type: DRUG
Intervention: Sustanon 250 mg ampule (Testosterone esters)
Description: Drug used for treatment of hypogonadism
Study: NCT01398033

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-coated balloon
Description: percutaneous transluminal angioplasty with a non-coated balloon
Study: NCT04711213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Dose 2
Description: Dexamethasone ophthalmic suspension dose 2
Study: NCT03901261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuro-imaging, Lumbar puncture
Description: Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
Study: NCT00448916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Orally-administered pregabalin
Study: NCT04311177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan; 25 mg daily; oral administration
Study: NCT01196715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alpha
Description: Aranesp 500 mcg vials once every 2 weeks.
Study: NCT04311177

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
Study: NCT01866878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: equipment rehabilitation stereognosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Study: NCT02559206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral, once daily
Study: NCT00539916

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular orange juice consumption
Description: 600 mL /day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular orange juice consumption
Description: 600 mL /day.
Study: NCT04583111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulpiride
Description: Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
Study: NCT02791971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SpeakOut
Description: SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Control Intervention
Description: The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
Study: NCT03933423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home based phototherapy and referral
Description: CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
Study: NCT02207595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use
Study: NCT01196715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: 300 mcg vials twice a week, 3-4 days apart

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Red Cell Transfusion
Description: Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
Study: NCT03937193

Intervention type: DIAGNOSTIC_TEST
Intervention: computerized tomography
Description: abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.

Intervention type: DIAGNOSTIC_TEST
Intervention: computerized tomography
Description: abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
Study: NCT03359694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT group
Description: Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ET group
Description: Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX group
Description: Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
Study: NCT04711213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 1
Description: Placebo suspension dose 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 2
Description: Placebo suspension dose 2
Study: NCT01659502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-118
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
Study: NCT04741334

Intervention type: DRUG
Intervention: direct anticoagulant
Description: exposure to direct anticoagulant

Intervention type: DRUG
Intervention: antiplatelet drugs
Description: exposure to antiplatelet drugs
Study: NCT01322971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally twice daily for seven days
Study: NCT02904759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Study: NCT01304758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS System
Description: Treatment with the ExAblate Transcranial MRgFUS System.
Study: NCT04741334

Intervention type: DRUG
Intervention: Dicumarols
Description: exposure to dicumarols
Study: NCT04452227

Intervention type: OTHER
Intervention: questionnaire
Description: Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
Study: NCT01536119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coparenting Breastfeeding Support Intervention
Description: The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
Study: NCT04486040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage
Description: Use of the suction drainage after hip revision arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-drainage
Description: Patients without drainage after surgery
Study: NCT03309267

Intervention type: PROCEDURE
Intervention: Intercostal block
Description: Intercostal block +patient controlled analgesia
Study: NCT04133415

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice stereotactic body radiation therapy
Description: -As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
Study: NCT03719014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross
Description: The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
Study: NCT01594242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib